Multiple Sclerosis Implementation Network (Registry)

Multiple Sclerosis Implementation Network

The Multiple Sclerosis Implementation Network (MSIN) is a collaboration between the Multiple Sclerosis Association of America (MSAA), The University of Texas Health Science Center at Houston (UTHealth Houston), Dell Medical School at The University of Texas at Austin, and Novartis Pharmaceuticals Corporation. The goal of MSIN is to improve Multiple Sclerosis (MS) care, patient health, and quality of life through the development and support of implementation research and clinical practice collaboration. MSIN brings together healthcare teams, people with MS, and research leaders in MS and implementation science (IS) to learn, share, test, implement, and disseminate innovations that improve MS care, patient health, and quality of life.

This ClinicalTrials.gov record pertains to the MSIN Patient Registry, which is a comprehensive database that integrates participants' electronic health records from various providers.

Study Overview

• Status: Recruiting
• Conditions: Multiple Sclerosis

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Amanda Montague, EdM; Phone Number: 800-532-7667; Email: AMontague@MYMSAA.org

Study Locations

• United States
  • New Jersey
    • Cherry Hill, New Jersey, United States, 08034
      • Recruiting
      • Multiple Sclerosis Association of America
      • Contact: Amanda Mantague, Ed.M.; Phone Number: 800-532-7667; Email: AMontague@MYMSAA.org
  • Texas
    • Austin, Texas, United States, 78712
      • Recruiting
      • The University of Texas at Austin
      • Contact: Leorah Freeman, MD, PhD; Phone Number: (713) 992-9213; Email: Leorah.Freeman@austin.utexas.edu
    • Houston, Texas, United States, 77030
      • Recruiting
      • The University of Texas Health Science Center at Houston (UTHealth Houston)
      • Contact: Maria E. Fernandez, PhD; Phone Number: (713) 500-9626; Email: Maria.E.Fernandez@uth.tmc.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Clinics in the United States treating MS patients.

Description

Inclusion Criteria:

• diagnosed with Multiple Sclerosis
• can speak and understand English comfortably

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patients with Multiple Sclerosis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Multiple sclerosis disability as assessed by the Patient-Determined Disease Steps (PDDS) Scale	Total score on the PDDS ranges from 0 (normal) to 8 (Bedridden: Unable to sit in a wheelchair for more than one hour), with a higher score indicating a worse outcome.	5 years
Perception of cognitive impairment as assessed by the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) Scale	Total score on the MSNQ ranges from 0 to 60, with a higher score indicating greater perceived cognitive impairment.	5 years

Collaborators and Investigators

• Sponsor: The University of Texas Health Science Center, Houston
• Collaborators: Novartis; Multiple Sclerosis Association of America; The University of Texas at Austin
• Investigators: Study Director: Amanda Montague, EdM, Multiple Sclerosis Association of America

Study record dates

Study Major Dates

• Study Start (Actual): April 28, 2025
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): December 31, 2030

Study Registration Dates

• First Submitted: January 29, 2026
• First Submitted That Met QC Criteria: February 9, 2026
• First Posted (Actual): February 17, 2026

Study Record Updates

• Last Update Posted (Actual): February 17, 2026
• Last Update Submitted That Met QC Criteria: February 9, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Autoimmune Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Multiple Sclerosis
• Other Study ID Numbers: HSC-SPH-24-0515 (Registry)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No